Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CASI CASI Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: CASI
Price (delayed)
$1.93
Market cap
$29.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.55
Enterprise value
$19M
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is
Highlights
CASI's revenue is up by 10% QoQ and by 8% YoY
CASI Pharmaceuticals's gross margin has decreased by 29% YoY but it has increased by 6% from the previous quarter
CASI's gross profit is down by 23% YoY but it is up by 16% QoQ
CASI Pharmaceuticals's net income has decreased by 33% YoY and by 3.1% from the previous quarter
CASI Pharmaceuticals's quick ratio has decreased by 30% from the previous quarter
Key stats
What are the main financial stats of CASI
Market
Valuations
Earnings
Shares outstanding
15.49M
Market cap
$29.9M
Enterprise value
$19M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.61
Revenue
$31.37M
Gross profit
$12.96M
Operating income
-$40.44M
Net income
-$40.48M
EBIT
-$39.47M
EBITDA
N/A
Free cash flow
N/A
Per share
Balance sheet
Liquidity
EPS
-$2.55
EPS diluted
-$2.55
Free cash flow per share
N/A
Book value per share
-$0.52
Revenue per share
$2.02
TBVPS
$2.62
Total assets
$40.82M
Total liabilities
$48.89M
Debt
$0
Equity
-$8.07M
Working capital
-$6.55M
Debt to equity
0
Current ratio
0.81
Quick ratio
0.6
Net debt/EBITDA
N/A
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
41.3%
Net margin
-129%
Operating margin
-128.9%
Return on assets
-77.3%
Return on equity
-972.6%
Return on invested capital
-159.3%
Return on capital employed
-555.3%
Return on sales
-125.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CASI stock price
How has the CASI Pharmaceuticals stock price performed over time
Intraday
3.76%
1 week
2.87%
1 month
-1.03%
1 year
-45.94%
YTD
-31.8%
QTD
-10.65%
Financial performance
How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$31.37M
Gross profit
$12.96M
Operating income
-$40.44M
Net income
-$40.48M
Gross margin
41.3%
Net margin
-129%
The operating income has contracted by 42% YoY and by 2.6% from the previous quarter
CASI Pharmaceuticals's net income has decreased by 33% YoY and by 3.1% from the previous quarter
CASI's operating margin is down by 31% YoY but it is up by 7% from the previous quarter
CASI Pharmaceuticals's gross margin has decreased by 29% YoY but it has increased by 6% from the previous quarter
Price vs fundamentals
How does CASI's price correlate with its fundamentals
Growth
What is CASI Pharmaceuticals's growth rate over time
Valuation
What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.61
CASI's EPS is down by 11% year-on-year
CASI's P/S is 84% below its 5-year quarterly average of 6.1 and 62% below its last 4 quarters average of 2.5
CASI's revenue is up by 10% QoQ and by 8% YoY
Efficiency
How efficient is CASI Pharmaceuticals business performance
CASI's ROIC is down by 29% from the previous quarter
The ROA has contracted by 27% from the previous quarter
CASI's return on sales is down by 21% year-on-year but it is up by 6% since the previous quarter
Dividends
What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CASI.
Financial health
How did CASI Pharmaceuticals financials performed over time
The total assets is 17% smaller than the total liabilities
CASI Pharmaceuticals's quick ratio has decreased by 30% from the previous quarter
CASI Pharmaceuticals's current ratio has decreased by 26% from the previous quarter
The debt is 100% greater than the equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.